**Lay Outcomes**

- We have one publication in preparation for submission this month and another for submission within the next six months.

- We have obtained R01 level funding from the NCI/NIH based on our findings.

- We have identified that PI3K inhibitors and direct targeting of SEMA7A may eradicate metastatic disease

- We are working toward novel clinical trials with available PI3K inhibitors and are commercializing our SEMA7A monoclonal antibody for future clinical trials in the next 3-5 years.